Rituximab

본문 바로가기


Home > Product > Rituximab
Selling leads
Rituximab
Posting date : Jul 21, 2025
Membership
Free Member Scince Jun 27, 2025
FOB Price
detailed discussion
Min. Order Quantity
1
Supply Abillity
hundreds of kgs
Port
Shanghai Port
Payment Terms
detailed discussion
Package
Convenient package
Keyword :
Category
Contact
Lena
Selling Leads Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
Royal
Model Number
+86 15242851296
HS-CODE
-
Package & Delivery Lead Time
Package
Convenient package
Detailed Description

Rituximab is a chimeric murine - human monoclonal antibody specifically targeting B cells. It recognizes and specifically binds to CD20, which is only expressed on the surface of pre-B cells and mature B cells, and efficiently and directionally exerts cytotoxic effects, anti-proliferative effects, and induces apoptosis. It continuously consumes B cells to produce blocking antibodies. Because CD20 does not occur in hematopoietic stem cells, normal plasma cells and other normal tissues, rituximab can effectively avoid extensive immunosuppression and has high safety. It was first approved by the US Food and Drug Administration for the treatment of non-Hodgkin's lymphoma.


ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2026 ECROBOT.COM. All rights reserved.
Top